Atlas Trials

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Clinical trial NCT06378190 · RECRUITING

Trial details

NCT number
NCT06378190
Sponsor
Instituto de Investigación Biomédica de Salamanca
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Refractory B-Cell LymphomaB-cell Lymphoma Recurrent
Start date
2024-03-11
Primary completion
2029-07-01
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.